BACKGROUND: The recently described A-->G (-3826) point mutation within the distal region of the UCP-1 promoter is possibly involved in the development of obesity, diabetes and related metabolic disorders. It was the aim of this study to examine the allelic frequency and the prevalence of the three UCP-1 genotypes in a broad caucasian cohort and to investigate the significance of this polymorphism for obesity and diabetes. METHODS: 1020 subjects were randomly chosen from 6450 participants in the Diabetomobile Study. The UCP-1 genotype was determined by genomic PCR and Bcl-I-RFLP analysis in 1020 subjects and tested for association with a variety of metabolic parameters. In addition, the influence of this mutation on adipocyte nuclear factor binding was investigated by electrophoretic mobility shift assays (EMSA). RESULTS: The genotype frequencies in 1020 subjects were: AA genotype, 57.0%; AG genotype, 35.4%; GG genotype, 7.6%; with allelic frequencies of 0.75 for allele A and 0.25 for allele G. No significant differences between the genotypes and age, gender, BMI, leptin, glucose, fasting insulin, C-peptide, HbA1c, diabetes manifestation, total cholesterol, and HDL cholesterol were found. Analysis of the Trp64Arg polymorphism of the beta3-adrenergic receptor in a subgroup of 343 subjects revealed no additive effect to the UCP-1 polymorphism. An yet unknown adipocyte-specific factor of nuclear extracts from 3T3-L1 adipocytes during differentiation is able to bind specifically to the distal UCP-1 promoter region and this binding ability can not be abolished by the mutation. CONCLUSIONS: We determined the genotype and allelic frequency of the UCP-1 promoter polymorphism in the largest known population-based study. The results from genotyping demonstrate clearly that this polymorphism does not play a major role in the pathogenesis obesity and diabetes. A yet unknown adipocyte derived and differentiation-dependent regulated transcription factor is able to bind to the distal UCP-1 promoter surrounding -3826 bp. This binding is not affected by presence of the mutation.
BACKGROUND: The recently described A-->G (-3826) point mutation within the distal region of the UCP-1 promoter is possibly involved in the development of obesity, diabetes and related metabolic disorders. It was the aim of this study to examine the allelic frequency and the prevalence of the three UCP-1 genotypes in a broad caucasian cohort and to investigate the significance of this polymorphism for obesity and diabetes. METHODS: 1020 subjects were randomly chosen from 6450 participants in the Diabetomobile Study. The UCP-1 genotype was determined by genomic PCR and Bcl-I-RFLP analysis in 1020 subjects and tested for association with a variety of metabolic parameters. In addition, the influence of this mutation on adipocyte nuclear factor binding was investigated by electrophoretic mobility shift assays (EMSA). RESULTS: The genotype frequencies in 1020 subjects were: AA genotype, 57.0%; AG genotype, 35.4%; GG genotype, 7.6%; with allelic frequencies of 0.75 for allele A and 0.25 for allele G. No significant differences between the genotypes and age, gender, BMI, leptin, glucose, fasting insulin, C-peptide, HbA1c, diabetes manifestation, total cholesterol, and HDL cholesterol were found. Analysis of the Trp64Arg polymorphism of the beta3-adrenergic receptor in a subgroup of 343 subjects revealed no additive effect to the UCP-1 polymorphism. An yet unknown adipocyte-specific factor of nuclear extracts from 3T3-L1 adipocytes during differentiation is able to bind specifically to the distal UCP-1 promoter region and this binding ability can not be abolished by the mutation. CONCLUSIONS: We determined the genotype and allelic frequency of the UCP-1 promoter polymorphism in the largest known population-based study. The results from genotyping demonstrate clearly that this polymorphism does not play a major role in the pathogenesis obesity and diabetes. A yet unknown adipocyte derived and differentiation-dependent regulated transcription factor is able to bind to the distal UCP-1 promoter surrounding -3826 bp. This binding is not affected by presence of the mutation.
Authors: Stefan-Martin Herrmann; Ji-Guang Wang; Jan A Staessen; Ercan Kertmen; Klaus Schmidt-Petersen; Walter Zidek; Martin Paul; Eva Brand Journal: J Mol Med (Berl) Date: 2003-03-28 Impact factor: 4.599
Authors: Anna E Pravednikova; Sergey Y Shevchenko; Victor V Kerchev; Manana R Skhirtladze; Svetlana N Larina; Zaur M Kachaev; Alexander D Egorov; Yulii V Shidlovskii Journal: Mol Med Date: 2020-05-25 Impact factor: 6.354
Authors: Petros C Dinas; Eleni Nintou; Maria Vliora; Anna E Pravednikova; Paraskevi Sakellariou; Agata Witkowicz; Zaur M Kachaev; Victor V Kerchev; Svetlana N Larina; James Cotton; Anna Kowalska; Paraskevi Gkiata; Alexandra Bargiota; Zaruhi A Khachatryan; Anahit A Hovhannisyan; Mariya A Antonosyan; Sona Margaryan; Anna Partyka; Pawel Bogdanski; Monika Szulinska; Matylda Kregielska-Narozna; Rafał Czepczyński; Marek Ruchała; Anna Tomkiewicz; Levon Yepiskoposyan; Lidia Karabon; Yulii Shidlovskii; George S Metsios; Andreas D Flouris Journal: PLoS One Date: 2022-04-28 Impact factor: 3.752
Authors: Letícia A Brondani; Tais S Assmann; Bianca M de Souza; Ana P Bouças; Luis H Canani; Daisy Crispim Journal: PLoS One Date: 2014-05-07 Impact factor: 3.240